Skip to the answer

Dasatinib

Dasatinib is a kinase inhibitor (a targeted cancer medicine) used to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) in adults and children.

Brand names SprycelPhyrago
Drug classes Cytochrome P450 3a4 Inhibitors
Rx Forms 2
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 16 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 6, 2026
Dasatinib at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Dasatinib is a targeted medicine for Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia that blocks several kinases (growth-signaling enzymes), including BCR-ABL, the abnormal protein driving these cancers; it is a standard first option and a common next step after imatinib, on the market since about 2006 and available as a generic. Many people tolerate it reasonably well, though tiredness, headache, diarrhea, rash and swelling are common, and fluid can collect around the lungs, especially in people over 65. The main concern is low blood counts and bleeding, so expect regular blood count and liver checks, and report unusual bruising, black stools, fever, swelling or breathlessness promptly.

Clinical pearls

  • Avoid acid reducers like omeprazole or famotidine, and space any antacid at least 2 hours away from your dasatinib dose.
  • Avoid grapefruit juice and St. John’s wort, and have every new prescription, including antibiotics and antifungals, checked for interactions.
  • Tell every prescriber and dentist you take dasatinib, since blood thinners, aspirin and other platelet-affecting drugs add to its bleeding risk.
  • Use effective birth control during treatment and for 30 days after the last dose, and that includes men with female partners.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asTablet, Oral suspension
Earliest FDA record2006
Companies listing it with the FDA17
FDA label last updatedAug 21, 2026
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Dasatinib, written from its FDA label.

What Dasatinib is used for

▾

Dasatinib treats certain Philadelphia chromosome-positive blood cancers.

  • Adults with newly diagnosed chronic phase Ph+ CML.
  • Adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML after resistance or intolerance to prior therapy including imatinib.
  • Adults with Ph+ ALL after resistance or intolerance to prior therapy.
  • Children 1 year and older with chronic phase Ph+ CML (Sprycel, Phyrago and the dasatinib tablet products).
  • Children 1 year and older with newly diagnosed Ph+ ALL together with chemotherapy (Sprycel, Phyrago and one generic dasatinib tablet product; not the dasatinib film-coated tablet product).

How Dasatinib works

▾

Dasatinib blocks several kinases, which are enzymes that send growth signals in cells. These include BCR-ABL, the abnormal protein behind Ph+ leukemia, and the SRC family kinases, c-KIT, EPHA2 and PDGFRβ.

In lab studies it was active against leukemia cells that were resistant to imatinib, including some with BCR-ABL mutations.

Dasatinib dosage

▾

Dasatinib tablets are taken by mouth once daily, in the morning or evening, with or without food. Swallow them whole. Do not crush, cut or chew.

  • Your starting dose depends on the type and phase of leukemia.
  • Children’s doses are based on body weight and are recalculated every 3 months or more often if needed.
  • For children with Ph+ ALL, treatment starts on or before day 15 of induction chemotherapy and continues for 2 years.

Follow your prescriber and label for dose and missed doses.

Dosing details from the FDA-approved label

From the Dasatinib prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Chronic phase CML in adults
    • 100 mg administered orally once daily (recommended starting dosage)
    • Consider dose escalation to 140 mg once daily in patients who do not achieve a hematologic or cytogenetic response at the recommended starting dosage
    • Swallow whole; do not crush, cut, or chew tablets. Can be taken with or without a meal, either in the morning or in the evening
  • Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults
    • 140 mg administered orally once daily (recommended starting dosage)
    • Consider dose escalation to 180 mg once daily in patients who do not achieve a hematologic or cytogenetic response at the recommended starting dosage
    • Swallow whole; do not crush, cut, or chew tablets. Can be taken with or without a meal, either in the morning or in the evening
  • Pediatric patients with CML or Ph+ ALL, body weight 10 to less than 20 kg
    • 40 mg once daily
    • Recalculate the dose every 3 months based on changes in body weight, or more often if necessary. Tablet dosing is not recommended for patients weighing less than 10 kg. For Ph+ ALL, begin on or before day 15 of induction chemotherapy and continue for 2 years
  • Pediatric patients with CML or Ph+ ALL, body weight 20 to less than 30 kg
    • 60 mg once daily
    • Recalculate the dose every 3 months based on changes in body weight, or more often if necessary. For Ph+ ALL, begin on or before day 15 of induction chemotherapy and continue for 2 years
  • Pediatric patients with CML or Ph+ ALL, body weight 30 to less than 45 kg
    • 70 mg once daily
    • Recalculate the dose every 3 months based on changes in body weight, or more often if necessary. For Ph+ ALL, begin on or before day 15 of induction chemotherapy and continue for 2 years
  • Pediatric patients with CML or Ph+ ALL, body weight at least 45 kg
    • 100 mg once daily
    • Recalculate the dose every 3 months based on changes in body weight, or more often if necessary. For Ph+ ALL, begin on or before day 15 of induction chemotherapy and continue for 2 years
  • Pediatric patients with chronic phase CML who do not achieve a hematologic or cytogenetic response at the starting dosage
    • Consider dose escalation to 120 mg once daily (see Table 2)
    • Maximum: 120 mg once daily
    • Dose escalation is not recommended for pediatric patients with Ph+ ALL receiving chemotherapy
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Chronic phase CML in adults: 100 mg once daily. (2) Accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults: 140 mg once daily. (2) Chronic phase CML and ALL in pediatrics: starting dose based on body weight. (2) Administer orally, with or without a meal. Do not crush, cut, or chew tablets. (2) 2.1 Dosage of Dasatinib Tablets in Adult Patients The recommended starting dosage of Dasatinib tablets for chronic phase CML in adults is 100 mg administered orally once daily. The recommended starting dosage of Dasatinib tablets for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults is 140 mg administered orally once daily. Tablets should not be crushed, cut, or chewed; they should be swallowed whole. Dasatinib tablets can be taken with or without a meal, either in the morning or in the evening. 2.2 Dosage of Dasatinib Tablets in Pediatric Patients with CML or Ph+ ALL The recommended starting dosage for pediatrics is based on body weight as shown in Table 1. The recommended dose should be administered orally once daily with or without food. Recalculate the dose every 3 months based on changes in body weight, or more often if necessary. Do not crush, cut or chew tablets. Swallow tablets whole. There are additional administration considerations for pediatric patients who have difficulty swallowing tablets whole [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3) ] . Table 1: Dosage of Dasatinib tablets for Pediatric Patients a Body Weight (kg) b Daily Dose (mg) a For pediatric patients with Ph+ ALL, begin Dasatinib tablet therapy on or before day 15 of induction chemotherapy, when diagnosis is confirmed and continue for 2 years. b Tablet dosing is not recommended for patients weighing less than 10 kg. 10 to less than 20 40 mg 20 to less than 30 60 mg 30 to less than 45 70 mg at least 45 100 mg Refer to Section 2.4 for recommendations on dose escalation in adults with CML and Ph+ ALL, and pediatric patients with CML. 2.3 Dose Modification Strong CYP3A4 Inducers Avoid the use of concomitant strong CYP3A4 inducers and St. John’s wort. If patients must be coadministered a strong CYP3A4 inducer, consider a Dasatinib tablets dose increase. If the dose of Dasatinib tablets is increased, monitor the patient carefully for toxicity [see Drug Interactions (7.1) ] .

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Dasatinib side effects

▾

Common side effects in people taking dasatinib alone include:

Common side effects

  • Low blood counts (myelosuppression)
  • Fluid retention
  • Diarrhea
  • Headache
  • Skin rash
  • Bleeding
  • Shortness of breath
  • Fatigue
  • Nausea
  • Muscle and bone pain

When to get medical help

  • Call your doctor right away for unusual bleeding, bruising, black stools or a severe headache. Dasatinib can cause serious and fatal bleeding.
  • Get help for fever, infection signs or extreme tiredness, which can come from low blood counts.
  • Report swelling, sudden weight gain, cough or trouble breathing. These can be fluid around the lungs or pulmonary arterial hypertension (high blood pressure in the lung arteries).
  • Seek care for chest symptoms, fainting or an irregular heartbeat. Dasatinib can affect the heart and the QT interval (heart rhythm timing).
  • Tell your doctor about severe skin or mouth reactions.
  • Report yellowing skin or eyes, or dark urine. Liver problems are possible.

Fluid around the lungs (pleural effusion) was the most common serious reaction. Call your doctor for bleeding, breathing trouble, fever or severe swelling.

Dasatinib warnings and precautions

▾
  • Low blood counts and bleeding: severe low platelets, white cells and red cells can occur, and serious or fatal bleeding is possible. Blood counts should be checked regularly.
  • Fluid retention: sometimes severe, including fluid around the lungs.
  • Heart and lung effects: cardiovascular toxicity, pulmonary arterial hypertension and QT prolongation.
  • Skin reactions: severe mucocutaneous (skin and mucous membrane) reactions have been reported.
  • Tumor lysis syndrome: keep well hydrated and have uric acid levels corrected before starting.
  • Liver: liver function should be checked before treatment and monthly after.
  • Pregnancy: can cause fetal harm.
  • Children: delayed bone fusion, osteopenia, slowed growth and gynecomastia (breast enlargement) have been reported.

Dasatinib interactions

▾

Several drugs and foods can change dasatinib levels or how it works.

  • Strong CYP3A4 inhibitors and grapefruit juice can raise levels and increase toxicity.
  • Strong CYP3A4 inducers can lower levels and reduce effectiveness. St. John’s wort should also be avoided per some labels.
  • H2 blockers and proton pump inhibitors can lower levels. Do not use them with dasatinib.
  • Antacids: avoid taking at the same time. Take 2 hours before or after dasatinib.
  • Blood thinners and platelet-affecting drugs raise bleeding risk.
  • High-dose methotrexate may clear more slowly.

Interactions listed in the FDA-approved label

From the Dasatinib prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Strong CYP3A4 inhibitors: May increase dasatinib concentrations, which may increase the risk of toxicity. Avoid concomitant use of strong CYP3A4 inhibitors and grapefruit juice. If it cannot be avoided, consider a dose decrease to 40 mg daily for patients taking 140 mg daily, or 20 mg daily for patients taking 100 mg or 70 mg daily. For patients taking 60 mg or 40 mg daily, consider interrupting until the inhibitor is discontinued; allow a washout period of appr
  • Strong CYP3A4 inducers: May decrease dasatinib concentrations, which may reduce efficacy. Avoid concomitant use; consider alternative drugs with less enzyme induction potential. If it cannot be avoided, consider a dose increase and monitor the patient carefully for toxicity.
  • Antacids: Gastric acid reducing agents may decrease dasatinib concentrations, which may reduce efficacy. Avoid simultaneous administration. If an antacid cannot be avoided, administer it at least 2 hours prior to or 2 hours after the dose.
  • H2 antagonists and proton pump inhibitors: May decrease dasatinib concentrations, which may reduce efficacy. Do not administer with dasatinib; consider the use of antacids in place of H2 antagonists or proton pump inhibitors.
  • Methotrexate: Dasatinib may delay the clearance of methotrexate and result in sustained methotrexate concentrations when methotrexate is used at high doses (> 500 mg/m2). Refer to the prescribing information for methotrexate injection for recommendations on management of methotrexate concentrations.
  • Grapefruit juice: Listed with strong CYP3A4 inhibitors to avoid. Avoid the use of grapefruit juice.
Read the label’s full interactions text

7 DRUG INTERACTIONS • Strong CYP3A4 Inhibitors: Dose reduction may be necessary. (2.3 , 7.1) • Strong CYP3A4 Inducers: Dose increase may be necessary. (2.3 , 7.1) • Antacids: Avoid simultaneous administration. (7.1) • H 2 Antagonists and Proton Pump Inhibitors: Avoid coadministration. (7.1) 7.1 Effect of Other Drugs on Dasatinib Strong CYP3A4 Inhibitors The coadministration with strong CYP3A inhibitors may increase dasatinib concentrations [see Clinical Pharmacology (12.3) ] . Increased dasatinib concentrations may increase the risk of toxicity. Avoid concomitant use of strong CYP3A4 inhibitors. If concomitant administration of a strong CYP3A4 inhibitor cannot be avoided, consider a SPRYCEL dose reduction [see Dosage and Administration (2.5) ] . Strong CYP3A4 Inducers The coadministration of SPRYCEL with strong CYP3A inducers may decrease dasatinib concentrations [see Clinical Pharmacology (12.3) ] . Decreased dasatinib concentrations may reduce efficacy. Consider alternative drugs with less enzyme induction potential. If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a SPRYCEL dose increase. Gastric Acid Reducing Agents The coadministration of SPRYCEL with a gastric acid reducing agent may decrease the concentrations of dasatinib. Decreased dasatinib concentrations may reduce efficacy. Do not administer H 2 antagonists or proton pump inhibitors with SPRYCEL. Consider the use of antacids in place of H 2 antagonists or proton pump inhibitors. Administer the antacid at least 2 hours prior to or 2 hours after the dose of SPRYCEL. Avoid simultaneous administration of SPRYCEL with antacids. 7.2 Effect of Dasatinib on Other Drugs Methotrexate SPRYCEL may delay the clearance of methotrexate and result in sustained methotrexate concentrations when methotrexate is used at high doses (> 500 mg/m 2 ). Refer to the prescribing information for methotrexate injection for recommendations on management of methotrexate concentrations.

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿146 supplements and herbs with documented Dasatinib interactions, ranked by severity Check Dasatinib against a supplement or herb →

Before taking Dasatinib

▾
  • There are no listed contraindications.
  • Pregnancy: it can harm a fetus. Use effective contraception during treatment and for 30 days after the last dose.
  • Do not breastfeed during treatment and for 2 weeks after the last dose.
  • It may affect fertility, based on animal data.
  • Children: there are no data under 1 year of age. Bone growth should be monitored.
  • Older adults: they are more likely to have fatigue, fluid around the lungs, diarrhea and shortness of breath, and should be monitored closely.
  • Tell your doctor about liver, heart or lung problems and QT prolongation.

Dasatinib overdose

▾

Overdose experience is limited. Two patients who took a high amount for a week developed severe low blood counts and bleeding. Anyone who takes more than prescribed should be monitored closely for low blood counts and given supportive treatment. Contact your doctor or poison control right away.

What Dasatinib does in the body

▾

Dasatinib can slightly lengthen the QT interval, a measure of heart electrical timing. At therapeutic doses, the maximum average increase was about 3 to 6 milliseconds. A small number of patients in trials had QTc values over 500 ms.

How your body processes Dasatinib

▾

Peak blood levels occur about 0.5 to 6 hours after a dose. A high-fat meal raised exposure by about 14%. The half-life is about 3 to 5 hours. The liver breaks it down mainly through CYP3A4. Most of it leaves through the feces, with little in urine. Age, sex and kidney function had no clinically relevant effect on levels.

How to store Dasatinib

▾

Dasatinib tablets should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) .

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

146

Supplements & herbs that interact with Dasatinib

146 supplements and herbal products have documented interactions with Dasatinib in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 8
  • Moderate · 98
  • Minor · 40
ACTIVATED CHARCOAL Major AMERICAN HELLEBORE Major ARSENIC Major CESIUM Major EPHEDRA Major GRAPEFRUIT Major SIDA CORDIFOLIA Major ST. JOHN'S WORT Major +138 more
Every supplement checked against Dasatinib — ranked by severity The full interaction hub: 8 major · 98 moderate · 40 minor · every one linked to its full report. Check Dasatinib against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Dasatinib: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Dasatinib — the kind of thing our pharmacy team would talk through with you at the counter.

What is dasatinib for?

▾
It treats certain leukemias that carry the Philadelphia chromosome. These are Ph+ chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). The exact approval depends on your age, disease phase and the product you take.

How should I take it?

▾
Take it by mouth once a day, with or without food. Swallow the tablet whole. Do not crush, cut or chew it. Follow your prescriber’s directions for your dose.

What side effects are common?

▾
Expect possible low blood counts, fluid retention, diarrhea, headache, rash, fatigue, nausea and shortness of breath. Call your doctor for bleeding, fever, swelling or trouble breathing.

Can I take my heartburn medicine with it?

▾
Usually not. H2 blockers and proton pump inhibitors can lower dasatinib levels, so they should not be used with it. If you need an antacid, take it at least 2 hours before or after dasatinib. Check with me or your doctor first.

Are there foods or other drugs I should avoid?

▾
Avoid grapefruit juice. Some other medicines also change dasatinib levels, including strong CYP3A4 inhibitors and inducers, and St. John’s wort per some labels. Always tell us about everything you take, including blood thinners.

Is it safe in pregnancy?

▾
No. Dasatinib can harm an unborn baby. Use effective contraception during treatment and for 30 days after your last dose. Do not breastfeed during treatment and for 2 weeks afterward.

Is Dasatinib available over the counter?

▾
No. Dasatinib is a prescription medicine: every Dasatinib product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Dasatinib first available?

▾
The earliest FDA record we hold for Dasatinib is from 2006: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Dasatinib was first used.

Who makes Dasatinib?

▾
17 companies currently list Dasatinib products in the FDA's NDC Directory, including Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Apotex Corp.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Dasatinib on HelloPharmacist

📊Dasatinib supplement interactions146 checked — ranked by severity 🌿Drug & Supplement CheckerDasatinib vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Dasatinib NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Dasatinib Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Dasatinib forms and strengths (how it comes)

Dasatinib is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Dasatinib inactive ingredients by manufacturer.

Tablet

By mouth
Brands Phyrago Sprycel
How this form is used
What it may be used for
  • Sprycel and Phyrago are used for Ph+ CML and Ph+ ALL in adults, and for chronic phase Ph+ CML and newly diagnosed Ph+ ALL (with chemotherapy) in children 1 year and older.
  • Dasatinib film-coated tablet is labeled for adult Ph+ CML and Ph+ ALL and for pediatric chronic phase Ph+ CML.
  • Another dasatinib tablet product is labeled for the same adult uses plus pediatric chronic phase CML and newly diagnosed Ph+ ALL with chemotherapy.
Important instructions
  • Sprycel and Phyrago tablets are taken by mouth once daily, with or without a meal.
  • Sprycel and Phyrago tablets should be swallowed whole, not crushed, cut or chewed.
  • Dasatinib tablets are likewise taken once daily by mouth, with or without food, and swallowed whole.
  • Sprycel and Phyrago tablet dosing in children is based on body weight and is not recommended under 10 kg.
Available strengths 6 strengths
20 mg 50 mg 70 mg 80 mg 100 mg 140 mg
144 FDA-listed product records ⓘ

Oral suspension

By mouth
Available strengths 1 strength
1 kg/kg
1 FDA-listed product record ⓘ

Dasatinib on the U.S. market: products, makers and brands

How Dasatinib appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

17 companies list 102 Dasatinib product records with the FDA, mostly as tablet, oral suspension; the earliest marketing or approval year on record is 2006. Brand names on the directory include Sprycel, Phyrago; the rest are generics.

2
Dose forms ⓘ
17
Labelers (makers, repackagers, distributors)
3
Brand names
102
FDA-listed product records ⓘ
2006
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (20) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Alembic Pharmaceuticals Inc.6%
Alembic Pharmaceuticals Limited6%
Apotex Corp.6%
Aurobindo Pharma Limited6%
AvKARE6%
Biocon Pharma Inc.6%
Other makers65%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Dasatinib is used (Medicaid data)

A general measure of how commonly Dasatinib is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Dasatinib is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

11,700
Medicaid prescriptions filled (Q1–Q4 2025)
$140M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Dasatinib prescribed? Of the 1,601 medications we measure, Dasatinib ranks #902 by Medicaid prescriptions — more than 44% of them.

Where Dasatinib ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #902 of 1,601
#897 Dextrose / Potassium C... 12,170 Rx #898 Nitroglycerin Transder... 12,007 Rx #899 Everolimus 11,955 Rx #900 Famciclovir 11,935 Rx #901 Cyclophosphamide Injec... 11,741 Rx #902 Dasatinib 11,700 Rx #903 Nateglinide 11,692 Rx #904 Doravirine 11,622 Rx #905 Sulfacetamide Ophthalm... 11,572 Rx #906 Bempedoic Acid 11,416 Rx #907 Acetaminophen / Aspiri... 11,352 Rx

Utilization by Dasatinib product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 100 mg oral tablet is the most-dispensed Dasatinib product — about 77% of these Medicaid prescriptions.

dasatinib 100 MG Oral Tablet Most dispensed

9,010 Medicaid prescriptions (Q1–Q4 2025) 77% of Dasatinib prescriptions shown $110.2M gross reimbursement (before rebates) ≈ $12,231 per prescription (gross)

Summed across the 7 of 18 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 799047

dasatinib 50 MG Oral Tablet

1,400 Medicaid prescriptions (Q1–Q4 2025) 12% of Dasatinib prescriptions shown $12.6M gross reimbursement (before rebates) ≈ $9,032 per prescription (gross)

Summed across the 4 of 18 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 643107

dasatinib 70 MG Oral Tablet

524 Medicaid prescriptions (Q1–Q4 2025) 4% of Dasatinib prescriptions shown $5.1M gross reimbursement (before rebates) ≈ $9,788 per prescription (gross)

Summed across the 5 of 18 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 643109

dasatinib 80 MG Oral Tablet

307 Medicaid prescriptions (Q1–Q4 2025) 3% of Dasatinib prescriptions shown $5.5M gross reimbursement (before rebates) ≈ $17,832 per prescription (gross)

Summed across the 4 of 18 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1045406

dasatinib 140 MG Oral Tablet

293 Medicaid prescriptions (Q1–Q4 2025) 3% of Dasatinib prescriptions shown $5.2M gross reimbursement (before rebates) ≈ $17,611 per prescription (gross)

Summed across the 4 of 18 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1045402

dasatinib 20 MG Oral Tablet

166 Medicaid prescriptions (Q1–Q4 2025) 1% of Dasatinib prescriptions shown $1.4M gross reimbursement (before rebates) ≈ $8,430 per prescription (gross)

Summed across the 2 of 18 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 643105

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Dasatinib, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 26 of 108 listed Dasatinib NDCs with Medicaid activity.

Compare Dasatinib products

A representative set of FDA-listed product records for Dasatinib — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 102 of 102 products — FDA National Drug Code Directory. See every product, package size and price: browse all 102 Dasatinib NDCs →

Dasatinib recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Dasatinib recalls since July 2021.

✅No Dasatinib recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Dasatinib RxCUI 475342 1 dose form · 6 strengths
  1. Dose form (SCDF) Oral Tablet RxCUI 643104 In current FDA listings
    Clinical drug / strength (SCD) 20 MG RxCUI 643105 50 MG RxCUI 643107 70 MG RxCUI 643109 80 MG RxCUI 1045406 100 MG RxCUI 799047 140 MG RxCUI 1045402

Look up RxCUI 475342 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Dasatinib costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Tablet · Oral 100 mg $591.18 per tablet NDC details & price history
Tablet, Film Coated · Oral 100 mg $26.46 per tablet NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Dasatinib brand names

Dasatinib is sold under 2 brand names in the FDA directory — Sprycel, Phyrago. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Sprycel Phyrago

Who makes Dasatinib: manufacturers and labelers

17 companies list Dasatinib products with the FDA. By number of product records, the largest are Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Apotex Corp.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Alembic Pharmaceuticals Inc. 6 Alembic Pharmaceuticals Limited 6 Apotex Corp. 6 Aurobindo Pharma Limited 6 AvKARE 6 Biocon Pharma Inc. 6 BluePoint Laboratories 6 Cycle Pharmaceuticals Ltd 6 Dr.Reddys Laboratories Inc 6 E.R. Squibb & Sons, L.L.C. 6 Lupin Pharmaceuticals, Inc. 6 NorthStar RxLLC 6 Novadoz Pharmaceuticals LLC 6 Prasco Laboratories 6 Teva Pharmaceuticals, Inc. 6 Zydus Lifesciences Limited 6 Zydus Pharmaceuticals USA Inc. 6

Dasatinib drug class (RxNorm)

Dasatinib belongs to the Kinase Inhibitor class.

Pharmacologic class Kinase Inhibitor
Drug family (ATC) BCR-ABL tyrosine kinase inhibitors
How it works Protein Kinase Inhibitors, Cytochrome P450 3A4 Inhibitors

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Dasatinib page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Aug 21, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Dasatinib.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Dasatinib after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
16
Finished products in the current FDA directory
102
Companies listing them (makers, repackagers, distributors)
17
FDA labeler codes behind them ⓘ
17
Linked representative label ⓘ
E.R. Squibb & Sons, L.L.C.
Linked label effective
Aug 21, 2026
Composite sections available
23
Linked SPL Set ID
4764f37b-c9e6-4ede-bcc2-8a03b7c521df
Linked SPL Document ID
860a6889-e984-452f-9f99-f4c68ba6eaca
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. E.R. Squibb & Sons, L.L.C. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →